How to access Imbruvica from the UAE, the named-patient import pathway, 2026
Reviewed by the Reserve Meds clinical operations team. Last reviewed: 2026-05-13.
An Emirati patient with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Waldenstrom macroglobulinemia, or chronic graft-versus-host disease after failure of one or more lines of systemic therapy, may receive a prescription for Imbruvica (ibrutinib) from their treating hematologist. Imbruvica is FDA-approved in the United States and co-marketed by Pharmacyclics (an AbbVie company) and Janssen. It is a first-generation Bruton tyrosine kinase (BTK) inhibitor administered by oral capsule or tablet. Local availability of Imbruvica in the UAE can be inconsistent: the drug may not be on every specialty pharmacy's standing formulary, the specific indication may not match what is locally registered, or the strength required may be back-ordered. When that happens, a named-patient import pathway through MoHAP remains a legitimate route for the patient whose physician has already prescribed the drug.
This guide explains the pathway, the documentation your physician needs, typical costs and indicative timing, and where Reserve Meds fits in.
Ask about Imbruvica in UAE
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
The clinical situation
Imbruvica is a first-generation covalent BTK inhibitor. Mechanism: a small-molecule irreversible inhibitor of Bruton tyrosine kinase that blocks B-cell receptor signaling in malignant B-cell clones and modulates immune effector cell function in cGVHD. Dosing: indication-specific, typically 420 mg orally once daily for CLL/SLL and WM, and 420 mg once daily for cGVHD, per FDA labeling. Baseline workup per FDA labeling includes CBC with differential, hepatitis B serology, baseline ECG, lipid panel, and bleeding history review. Other important warnings include hemorrhage, serious infections including opportunistic infections, cytopenias, atrial fibrillation and flutter and ventricular arrhythmias, hypertension, second primary malignancies including non-melanoma skin cancer, and tumor lysis syndrome. Your hematologist will discuss the risk-benefit profile and schedule monitoring before initiating therapy.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
Is Imbruvica legally importable into the UAE?
Yes, through the UAE Ministry of Health and Prevention (MoHAP) named-patient and personal-use import framework, coordinated through an Emirati-licensed treating facility's pharmacy. The UAE has an established pathway for specialty medicines approved by reference authorities (US FDA, EMA, MHRA) but not stocked or registered for the specific indication locally.
The MoHAP named-patient route allows an Emirati-licensed physician to request import of a medicine when: (a) the medicine is approved by a recognised reference authority, (b) no clinically equivalent locally registered alternative is suitable for the patient's indication and history, (c) the treating physician takes clinical responsibility for use, and (d) chain of custody is documented from the US source to the administering facility. Applications are typically filed through the dispensing institution's import pharmacy on the physician's behalf, with approval issued on a per-patient, per-cycle quantity basis.
How the pathway works, step by step
- Consultation with your treating hematologist. The prescribing decision is clinical. Your hematologist documents the indication, prior therapies where relevant, and rationale for Imbruvica.
- Baseline screening. CBC with differential, hepatitis B serology, baseline ECG, lipid panel, and bleeding history review are confirmed and documented.
- MoHAP named-patient application. Your hematologist or the facility's import pharmacy files the application with clinical rationale, patient reference, product strength, quantity requested, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed pharmaceutical wholesale partner to secure product from Pharmacyclics' authorised distribution under DSCSA chain-of-custody.
- Arrival and first dose. The dispensing pharmacy releases product against the physician's prescription, and your hematologist initiates therapy.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming diagnosis (CLL/SLL, WM, or cGVHD), prior therapies where relevant, and Imbruvica as the indicated next step
- Verification of their Emirati medical licence
- A patient identifier, anonymised reference where privacy is preferred
- Documented pre-treatment screening consistent with FDA labeling (see above)
- The planned dosing regimen (indication-specific, per FDA labeling)
- A monitoring plan covering CBC at regular intervals, atrial fibrillation surveillance, infection vigilance, blood pressure monitoring, and hepatitis B reactivation monitoring
Reserve Meds provides a physician documentation kit tailored for BTK inhibitor therapies, including the templates MoHAP reviewers commonly request.
Typical costs and indicative timing
Reserve Meds gives you a transparent, itemised custom quote at intake. Medicine price: quote on request. You get a written quote for your case before you commit. International logistics, MoHAP documentation handling, and coordination add incremental cost. The delivered quote we issue at intake shows each line separately.
We give you a written timeline estimate for your case before you commit. Refills ship on a rolling cadence aligned to the dosing schedule.
Where Reserve Meds fits in
Reserve Meds is a US-based digital health company that coordinates access to cross-border specialty medicine. For Imbruvica specifically, we provide:
- Sourcing. Through our US-licensed pharmaceutical wholesale partner, operating under DSCSA chain-of-custody from manufacturer to export.
- Documentation. Regulatory package tailored for your physician and for MoHAP review, including BTK inhibitor class templates.
- Logistics. Internationally tracked shipment to your named dispensing facility with tamper-evident packaging.
- Dedicated case lead. A named point of contact for your family and your physician across the full case arc.
We are a coordinator. We are not the prescriber, not a pharmacy, and not a dispensing facility. All clinical decisions remain with your treating hematologist, and dispensing sits with the licensed Emirati pharmacy of record. Reserve Meds operates on cash-pay only and does not bill insurance.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP named-patient and personal-use framework with appropriate documentation, clinical rationale, and a licensed dispensing facility. The pathway is routinely used across oncology, rare disease, and immunology at Emirati tertiary centers.
Will my private health insurance cover this? Cash-pay is the default posture. Some Emirati private insurance plans review named-patient imports case-by-case on a pre-authorisation basis when the documentation package is strong. We supply documentation for your submission but do not process insurance claims.
How does Imbruvica compare to Calquence and Brukinsa? All three are covalent BTK inhibitors. Ibrutinib is first-generation; acalabrutinib and zanubrutinib are second-generation with greater target selectivity and have shown reduced cardiovascular toxicity relative to ibrutinib in head-to-head CLL data. Choice between them is a clinical decision your hematologist will make based on cardiac history, drug interactions, and indication.
What if my physician has not filed a named-patient request before? Named-patient import is an institutional process most major Emirati tertiary centers (Cleveland Clinic Abu Dhabi, Tawam Hospital Al Ain, American Hospital Dubai, and Mediclinic City Hospital) have encountered. Our documentation kit is written for first-time applicants and tracks what MoHAP reviewers commonly ask for.
Next step
For Imbruvica coordination in the UAE, start your case at the portal or message us on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.
Composite case examples. This content is for general information and does not constitute medical advice.
Abu Dhabi and Dubai
This guide covers the whole UAE, including Abu Dhabi and Dubai. At federal level, medicines are regulated by the Emirates Drug Establishment (EDE) and the Ministry of Health and Prevention (MOHAP). MOHAP also issues permits to import medicines for personal use. Hospitals, clinics and doctors are licensed by the health authority of their own emirate: the Department of Health Abu Dhabi (DoH) in Abu Dhabi, and the Dubai Health Authority (DHA) in Dubai.
In practice, the hospital that treats you follows the rules of its own emirate, so the paperwork is prepared for that hospital. Tell us which hospital or doctor is treating you, in Abu Dhabi, Dubai or another emirate, and we prepare the document pack for that route.
Sources: Department of Health Abu Dhabi; Dubai Health Authority, Health Regulation Sector; MOHAP, permit to import medicines for personal use; Simmons & Simmons, UAE pharmaceutical law and the Emirates Drug Establishment.
Frequently asked questions
How can I get Imbruvica in the UAE if it is not approved or available there?
Reserve Meds coordinates US-sourced Imbruvica for patients in the UAE through a legal named-patient pathway, working with your treating doctor. Your treating physician provides the prescription and clinical justification; Reserve Meds prepares the named-patient documentation for the UAE and arranges DSCSA-compliant US sourcing and delivery to your physician or hospital pharmacy.
Can I access Imbruvica in the UAE through a named-patient import?
Often, yes. Named-patient access (sometimes called personal import) is the legal route we use for FDA-approved medicines such as Imbruvica. It is different from compassionate use, which covers investigational medicines through the manufacturer's own program; we do not supply investigational medicines. Eligibility and paperwork depend on the regulator in the UAE, and Reserve Meds maps the specific pathway for each market it coordinates.
Do I need a prescription to access Imbruvica in the UAE through Reserve Meds?
Yes. Reserve Meds is not a pharmacy and does not prescribe. A valid prescription and clinical justification from your treating physician are required, and all clinical decisions remain with your physician.
How does Reserve Meds deliver Imbruvica to a patient in the UAE?
Medicines are supplied through a US-licensed pharmaceutical wholesale partner, and Reserve Meds coordinates delivery of Imbruvica to your treating physician or hospital pharmacy in the UAE, with appropriate handling for the product.
How long does it take, and what does Imbruvica in the UAE cost through Reserve Meds?
After a short intake, the clinical team responds within one business day with case-specific feasibility, an indicative timeline, and a formal written quote. Cost depends on the destination, the prescribed regimen, and the duration of therapy, and is confirmed in writing before anything proceeds.
How do I start a request for Imbruvica in the UAE?
Submit a 60-second intake through the Reserve Meds patient portal, or message our team on WhatsApp. We reply within one business day. On WhatsApp we usually reply the same day.